Axcelead

What Axcelead does

Axcelead Drug Discovery Partners is Japan's first integrated drug discovery solution provider, offering end-to-end preclinical services spanning target identification, lead generation and optimization, DMPK, safety assessment, and IND-enabling nonclinical development under a single organization. Founded in July 2017 as a spin-out from Takeda Pharmaceutical's drug discovery research platform and headquartered in Kanagawa, Japan, the company inherited a proprietary 1.5 million+ compound library, ~1,000 historical drug discovery projects, and experienced research staff that underpin its current platform. Axcelead became fully independent from Takeda in April 2019 via share transfer to the Drug Discovery Innovation Fund managed by WHIZ PARTNERS and transitioned to a holding company structure (Axcelead Inc. as parent) in April 2020.

The company's service portfolio is organized across screening (HTS, HT-ASMS, phenotypic screening, iPS cell-based screening, and newly licensed DEL from Nissan Chemical), chemistry (medicinal, computational, flow, parallel synthesis), biology (omics, gene-modified animal models, disease model animals), DMPK (HT-ADMET, nonclinical PK/PD, modeling and simulation), and safety (in vitro toxicity, cardiovascular safety, GLP toxicology). Modality coverage extends across small molecules, targeted protein degraders (PROTAC and molecular glues), peptides, nucleic acids, mRNA, and regenerative medicine. Its A-HiT (Axcelead Hit-identified Target) project retains approximately 120 pre-validated targets with hit/lead compounds available for partnership or licensing.

Axcelead generates revenue through project-based service contracts with custom quotes, serving nearly all Japanese pharmaceutical companies investing in drug discovery, multiple global megapharma, biotech ventures, and academic/government institutions, with reported metrics of 95% hit identification success, 88% repeat rate, and 84% lead generation/optimization achievement. AI/ML capabilities are layered primarily through partnerships: FRONTEO for NLP-based target discovery, Schrödinger for computational chemistry, and Eli Lilly's TuneLab federated learning platform (joined June 2026 as the first CRO participant). 2026 has seen three major strategic partnerships (Lilly TuneLab, Proteros for EU/US structural biology, Nissan Chemical for DEL) alongside a refreshed leadership under President Yamada Nobuhiko.

Name

Axcelead

Legal name

Axcelead Drug Discovery Partners株式会社

Website

https://axcelead.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Axcelead Drug Discovery Partners is Japan's first integrated drug discovery solution provider, offering end-to-end preclinical services from target identification through IND filing to pharmaceutical companies, biotech ventures, and academic institutions.

Ownership category

akta.pro rank

Product category

Drug Discovery CRO Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), DMPK / ADME & Bioanalysis (HLAGAFAC), Nonclinical Study Management & Regulatory Writing (IND-enabling) (HLAGAFAN), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Drug discovery services
• Preclinical CRO services
• High-throughput screening
• Medicinal chemistry
• ADME safety assessment

Headquarters

HQ city

Kanagawa

HQ country

Japan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Core offering

Axcelead Drug Discovery Partners provides integrated, one-stop drug discovery contract research services spanning the entire preclinical pipeline from target identification through IND filing. Its offerings include high-throughput screening (HTS) with a proprietary 1.5 million+ compound library, medicinal and computational chemistry, biology and omics, nonclinical DMPK and PK/PD modeling, in vitro and in vivo safety assessment, and modality-specific discovery solutions for small molecules, targeted protein degraders, peptides, nucleic acids, mRNA, and regenerative medicine. These services are delivered to pharmaceutical companies, biotech ventures, and academic/government research institutions on a project-based CRO engagement model.

Product overview

Axcelead Drug Discovery Partners (Axcelead DDP) is Japan's first drug discovery solution provider (PRO: Partnership Research Organization), offering an integrated one-stop drug discovery platform spanning the entire preclinical pipeline from target identification through IND filing. The platform consists of a comprehensive suite of services organized across five core areas: (1) Screening — including High-Throughput Screening (HTS) using a 1.5M+ compound library (700+ projects, 90%+ hit rate), HT-ASMS, phenotypic screening, and DEL services (Nissan Chemical licensed); (2) Chemistry — medicinal chemistry, computational chemistry, parallel synthesis, flow chemistry, and analytical chemistry; (3) Biology — pharmacodynamics, omics analysis (single-cell, spatial transcriptomics), bioinformatics, gene-modified animal models, and iPS cell-based screening; (4) DMPK — HT-ADMET, nonclinical PK/PD studies, PBPK, and PK/PD modeling & simulation; and (5) Safety — in vitro toxicity screening (hERG, multi-ion channel), in vivo safety pharmacology, GLP toxicology, and nonclinical development consulting. Key modality-specific services include Targeted Protein Degradation (TPD) solutions for both chimera and molecular glue degraders, small molecule drug discovery, peptide, nucleic acid, mRNA, and regenerative medicine support. AI capabilities are enhanced through partnerships with Lilly TuneLab (federated learning), FRONTEO (NLP-based target discovery), and Schrödinger (computational chemistry). The A-HiT (Axcelead Hit-identified Target) project provides approximately 120 pre-validated target assets with existing hit/lead compounds and assay systems.

Differentiator

Problem solved

Functional benefit

Products and services

• High-Throughput Screening (HTS)
• Protein Degradation Inducer (TPD) Drug Discovery Solution
• Low-Molecule Drug Discovery
• Peptide Drug Discovery
• Nucleic Acid Drug Discovery
• mRNA Drug Discovery
• HT-ADMET (High-Throughput ADME)
• Kinase Platform
• Drug Repositioning
• Project Co-Creation Solution (PJ共創型ソリューション)
• Nonclinical Development PK/PD
• Modeling & Simulation × Biomarker Discovery
• In Vitro Toxicity Screening
• Cardiovascular Safety Assessment
• Nonclinical Safety Evaluation Package
• Gene-Modified Animal Model Services
• Omics Services
• Compound Management
• Medicinal Chemistry
• Flow Chemistry
• Nonclinical Development Consulting
• iPS Cell-Based Compound Screening
• HT-ASMS (High-Throughput Affinity Selection-Mass Spectrometry)
• Phenotypic Drug Discovery
• RNA Splicing Drug Discovery Library
• Regenerative Medicine Support
• DNA-Encoded Library (DEL) Services

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability8 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Domainex: Integrated drug discovery CRO providing medicinal chemistry, in vitro pharmacology, and protein production services. Directly comparable integrated discovery model focused on biotech and pharma clients.
• Evotec SE: Global integrated drug discovery CRO offering end-to-end services from target identification through preclinical and partnered clinical development. Closely comparable business model to Axcelead's integrated one-stop platform, with a broader modality footprint and global scale.
• Pharmaron: Global CRO/CDMO providing integrated drug discovery and development services across chemistry, biology, DMPK, safety, and formulation. Directly comparable integrated one-stop model serving pharma and biotech clients.
• Crown Bioscience: Preclinical CRO offering translational drug discovery and development services including in vivo pharmacology, oncology models, and biomarker services — overlapping with Axcelead's preclinical biology and in vivo capabilities.
• Sygnature Discovery: Integrated drug discovery CRO offering medicinal chemistry, in vitro biology, DMPK, and computational chemistry. Closely comparable integrated service model targeting pharma and biotech clients.
• Eurofins Discovery: Offers integrated drug discovery services including medicinal chemistry, in vitro pharmacology, ADME/DMPK, and in vivo pharmacology — overlapping directly with Axcelead's screening, chemistry, biology, and DMPK service lines.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO with extensive drug discovery and preclinical services in chemistry, biology, and DMPK. Overlaps with Axcelead's services but operates at much larger scale with broader geographic coverage.
• Charles River Laboratories: Large incumbent CRO/CDMO with discovery, safety assessment, and manufacturing services. Overlaps with Axcelead's preclinical discovery and safety evaluation capabilities but at much greater scale and breadth.
• Curia: Global CRO/CDMO offering drug discovery, development, and manufacturing services. Overlaps with Axcelead's discovery and preclinical offerings but with significantly broader service breadth including API manufacturing.

Regional players

• CMIC Holdings: Japan's largest domestic CRO, providing clinical and preclinical drug development services. Comparable as a Japanese CRO peer serving pharma clients, though with greater emphasis on clinical rather than discovery services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat8 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@AxceleadDrugDiscoveryPartners
• Facebookfacebook.com/Axcelead
• LinkedInlinkedin.com/company/axcelead-ddp-japan

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axcelead